Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-arm, Open-label, Phase 1b Study to Explore the Mechanism of Action and Evaluate the Safety of Ontamalimab in Participants With Nonalcoholic Steatohepatitis With Fibrosis Stage 1 Through 4

NCT07052682 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT07052682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07052682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-arm, Open-label, Phase 1b Study to Explore the Mechanism of Action and Evaluate the Safety of Ontamalimab in Participants With Nonalcoholic Steatohepatitis With Fibrosis Stage 1 Through 4
Lead sponsor
Takeda
Phase
Phase 1
Overall status
Terminated
Start date
January 18, 2023
Completion date
December 30, 2024
Enrollment
11 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

steatohepatitis